Study of Hydroxyurea to Treat Sickle Cell Disease

NCT02868138 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2016-08-16

No results posted yet for this study

Summary

The aim of this single-center observational study was to evaluate quality of life, clinical effectiveness, and satisfaction in pediatric and young adult patients with sickle cell disease receiving hydroxyurea.

Conditions

Sponsors & Collaborators

  • Mersin University

    lead OTHER

Principal Investigators

  • BAHAR TUNCTAN, Ph.D. · MERSIN UNIVERSITY FACULTY OF PHARMACY DEPARTMENT OF PHARMACOLOGY

Eligibility

Min Age
7 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868138 on ClinicalTrials.gov